The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the obesity-drug market.
Source link
Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound
Date:
More like thisRelated
Peter Attia leaves CBS News contributor role amid fallout from Epstein files
The celebrity doctor Peter Attia is stepping down as...
UNM Hospital gets $500K grant to expand pathogen treatment capabilities
ALBUQUERQUE, N.M. (KRQE) – The University of New Mexico Hospital...
What Life Was Like for a Country Fan in the 1990s [PICTURES]
What was life really like for a country fan...
Former DJ Gets Prison Sentence for Scamming World’s Top Airlines
The entrepreneur sold tens of thousands of counterfeit aircraft...